Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 560.00
Bid: 550.00
Ask: 566.00
Change: 10.00 (1.82%)
Spread: 16.00 (2.909%)
Open: 568.00
High: 568.00
Low: 550.00
Prev. Close: 550.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

2 Sep 2020 07:00

RNS Number : 7412X
Gooch & Housego PLC
02 September 2020
 

For immediate release

2 September 2020

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Trading Update

 

"Trading in line with expectations"

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, provides an update for the 10 months ended 31 July 2020. Overall, trading remains in line with management's expectations for the full year ending 30 September 2020.

Trading

The Group's manufacturing locations in the UK, USA and China are now fully open, thanks to measures that were quickly and efficiently put in place by our site teams, minimising the disruption of the COVID-19 pandemic for our customers whilst keeping our employees safe. Most recently, our Torquay site in the UK has returned to full capacity.

Trading levels in June and July reflected the recovery in the Company's manufacturing capacity and some of our larger customers' manufacturing sites reopening.

Orders for fibre optics, hi- reliability fibre couplers for undersea cables and our A&D and life science capabilities remain robust. There continues to be improved demand for medical diagnostics, in particular for ventilator systems. As previously communicated, industrial laser demand remains at below "normalised" levels, although the semiconductor subsector has demonstrated sustained improvement.

The previously announced cost control measures have been implemented and will support the Group's profitability in H2 FY '20 and beyond.

Priorities in the COVID-19 emergency

Our primary concern during the emergency is the health and safety of our staff, customers and suppliers. Extensive measures have been put in place at all of our sites to ensure we rigorously meet social distancing and cleanliness requirements and all other relevant guidelines and regulations.

Financial strength

The Company remains in a good financial position with a strong balance sheet and liquidity levels that have continued to improve during the period. Total headroom increased to £28.1 million; this included a $10 million extension to the Group's revolving credit facility taking the total to $50 million, as announced in April 2020.

Outlook

There remains significant global economic uncertainty due to the COVID-19 emergency in the short term. That said, our telecommunications, A&D and life sciences businesses have held up well during the period, though the timing and pace of the industrial laser market recovery remains difficult to predict.

Improved industrial laser demand will be driven by technical innovation such as 5G and new laser based manufacturing techniques. There remains substantial long term growth potential for our photonic technologies and system capabilities in all of our target sectors.

The streamlining of our manufacturing sites is on schedule and will deliver the profit improvements previously announced.

 

Mark Webster, Chief Executive Officer of Gooch and Housego, commented:

"We are proud of the way that our staff and management have responded to the COVID-19 emergency. All of our sites in the UK, USA and China are now open and fully compliant with all relevant health and safety requirements. This has been achieved, quickly, efficiently and most importantly, safely.

"While there remains considerable short term economic uncertainty our order book remains robust, the Company's balance sheet has strengthened during the period and we have continued to invest in our high priority R&D targets.

"The COVID-19 emergency has validated G&H's long term strategy of diversification and moving up the value chain. We will continue to pursue this policy through internal investment and where appropriate, acquisitions."

 

 

 

 

For further information contact: -

 

Mark Webster/Chris Jewell

Gooch & Housego PLC

01460 256440

Mark Court/ Charlotte Slater

Buchanan

020 7466 5000

Chris Baird/Patrick Robb/

David Anderson

Investec Bank plc

020 7597 5970

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSSDESFESSEFU
Date   Source Headline
1st Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Jun 20202:53 pmRNSDirector/PDMR Shareholding
2nd Jun 202011:37 amRNSDirector/PDMR Shareholding
2nd Jun 20207:00 amRNSInterim Results
18th May 20207:00 amRNSNotification of Half Year Results
11th May 20207:00 amRNSAppointment of Non-Executive Director
23rd Apr 20204:23 pmRNSHolding(s) in Company
9th Apr 20203:25 pmRNSHolding(s) in Company
7th Apr 20207:00 amRNSHalf Year Trading Update
27th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20204:42 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSUS Facilities Update
17th Mar 20201:22 pmRNSFremont Facility Update
16th Mar 20201:56 pmRNSDirector/PDMR Shareholding
6th Mar 20209:45 amRNSDirector Share Purchase
3rd Mar 20207:00 amRNSStreamlining of Manufacturing
19th Feb 202012:23 pmRNSResult of AGM
19th Feb 20207:00 amRNSAGM Trading Update
3rd Feb 202012:08 pmRNSIssue of Equity and Total Voting Rights
14th Jan 202010:21 amRNSGrant of LTIP Awards
27th Dec 20193:26 pmRNSDirectorate: David Bauernfeind
11th Dec 20197:00 amRNSPosting of Annual Report and AGM Notice
9th Dec 20198:50 amRNSHolding(s) in Company
3rd Dec 20197:00 amRNSPreliminary Results
20th Nov 20198:42 amRNSBlock listing Interim Review
15th Nov 20194:41 pmRNSSecond Price Monitoring Extn
15th Nov 20194:35 pmRNSPrice Monitoring Extension
11th Nov 201911:18 amRNSConfirmation of Directorate Change
8th Nov 201912:54 pmRNSTotal Voting Rights
7th Oct 20197:00 amRNSFull Year Trading Update and Results Notification
6th Aug 201912:02 pmRNSPrice Monitoring Extension
18th Jul 201910:11 amRNSChief Financial Officer Appointment Timing Update
1st Jul 201910:57 amRNSDirector/PDMR Shareholding
6th Jun 201912:58 pmRNSDirector Share Purchase
4th Jun 20194:23 pmRNSDirectors' Share Purchases
4th Jun 20197:00 amRNSDirectorate Change
4th Jun 20197:00 amRNSInterim Results
28th May 20199:52 amRNSHolding(s) in Company
9th May 20197:00 amRNSNotification of Half Year Results
30th Apr 20197:00 amRNSAppointment of Chief Financial Officer
9th Apr 20197:00 amRNSCapital Markets Day
9th Apr 20197:00 amRNSHalf Year Trading Update
28th Mar 20195:28 pmRNSDirector/PDMR Shareholding
28th Mar 20195:25 pmRNSDirector/PDMR Shareholding
28th Mar 20195:24 pmRNSDirector/PDMR Shareholding
25th Mar 20195:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSITL signs manufacturing agreement with OrganOx
25th Feb 201911:27 amRNSDirector Share Purchase
21st Feb 20192:58 pmRNSDirector Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.